Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02571998 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

A Phase 2 study of Acne Vulgaris, sponsored by Maruho Co..

Completed
Registry status
Phase 2
Development phase
320
Enrollment target
20
Study locations

NCT02571998: Completed Phase 2 study of Acne Vulgaris, sponsored by Maruho Co..

NCT02571998 is a Phase 2 study of Acne Vulgaris that has completed, run by Maruho Co.. The registered enrollment target is 320 participants, above the 271-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02571998, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Maruho Co..

COMPLETED
Registry status
Phase 2
Development phase
320 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the safety and efficacy of Omiganan (CLS001) topical gel compared to vehicle topical gel applied once daily for 12 weeks in female subjects with moderate to severe inflammatory acne vulgaris.

Conditions Studied

Acne Vulgaris

Interventions

  • DRUG Vehicle Topical Gel
  • DRUG Omiganan (CLS001) Topical Gel

Study Locations (20)

Florida

  • - Boca Raton
  • - Boynton Beach
  • - Miami
  • - Pinellas Park
  • - Sanford
  • - Tampa

California

  • - Santa Ana
  • - Santa Monica

New York

  • - New York
  • - Stony Brook

Alabama

  • - Mobile

Arizona

  • - Phoenix

Colorado

  • - Denver

Massachusetts

  • - Beverly

Michigan

  • - Fort Gratiot

Trial Details

FieldValue
Enrollment Target 320 participants
Start Date 2015-10
Est. Completion 2016-08
Phase Phase 2
Maruho Co.

10 total trials

What the finished NCT02571998 record still lists

NCT02571998 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 271-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (18% higher).

The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Topical Gel is the first listed.

NCT02571998 names 20 study sites across 13 states, led by Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT02571998 about?

NCT02571998 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris". The primary objective of this study is to evaluate the safety and efficacy of Omiganan (CLS001) topical gel compared to vehicle topical gel applied once daily for 12 weeks in female subjects with moderate to severe inflammatory acne vulgaris.

What is the current status of trial NCT02571998?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2015-10. Estimated completion is 2016-08.

What conditions does trial NCT02571998 study?

This clinical trial studies the following conditions: Acne Vulgaris.

What interventions are being tested in trial NCT02571998?

The interventions under investigation include: Vehicle Topical Gel (DRUG), Omiganan (CLS001) Topical Gel (DRUG).

Who is sponsoring clinical trial NCT02571998?

This trial is sponsored by Maruho Co., which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02571998 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acne Vulgaris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02571998's enrollment target sits among peer trials

320 23rd of 67 higher than 45 of 67 other Acne Vulgaris trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02763683 · 320 participants

    Investigations of Dementia in Parkinson Disease

  • NCT03331198 · 320 participants · Phase 1

    Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

  • NCT03458832 · 320 participants

    Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

  • NCT03551951 · 320 participants

    Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02571998, the US trial registry maintained by the National Library of Medicine. NCT02571998 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.